Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 8, 2011, Pages 1726-1730

  Sylvester, Francisco A ^a,b,h   Turner, Dan ^c,d   Draghi II, Andrew ^a   Uuosoe, Krista ^d   McLernon, Robin ^d   Koproske, Kristen ^a   MacK, David R ^e   Crandall, Wallace V ^f   Hyams, Jeffrey S ^a   Leleiko, Neal S ^g   Griffiths, Anne M ^d  

^a Farmington   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g HASBRO CHILDREN'S HOSPITAL   (United States)

^h SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

children; corticosteroids; osteoprotegerin; ulcerative colitis

Indexed keywords

CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; LACTOFERRIN; METHYLPREDNISOLONE; OSTEOPROTEGERIN;

ADOLESCENT; ARTICLE; CHILD; COLON RESECTION; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COLECTOMY; COLITIS, ULCERATIVE; FECES; FEMALE; HOSPITALIZATION; HUMANS; MALE; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 79960278336     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21561     Document Type: Article

References (22)

1. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996; 129: 81-88. (Pubitemid 26277250)
2. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008; 57: 331-338. (Pubitemid 351288098)
3. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 423-432. (Pubitemid 47193130)
4. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010; 138: 2282-2291.
5. Skinner A, Lerer T, Wyzga N, et al. Fecal osteoprotegerin: a marker for pediatric ulcerative colitis at diagnosis - a pilot study. Gastroenterology. 2008; 134: A-205.
6. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309-319. (Pubitemid 27199902)
7. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273: 14363-14367. (Pubitemid 28319153)
8. Chakravarti A, Marceau AA, Flamand L, et al. Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab Invest. 2008; 88: 171-184. (Pubitemid 351161269)
9. Vitovski S, Phillips JS, Sayers J, et al. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007; 282: 31601-31609. (Pubitemid 350044899)
10. Vidal K, Serrant P, Schlosser B, et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G836-844. (Pubitemid 39280442)
11. Shipman CM, Croucher PI., Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003; 63: 912-916. (Pubitemid 36278418)
12. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010; 59: 1207-1212.
13. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 32: 171-177. (Pubitemid 32280632)
14. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009; 48: 48-54.
15. Sidler MA, Leach ST, Day AS., Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008; 14: 359-366. (Pubitemid 351441325)
16. Czub E, Herzig KH, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42: 1147-1150. (Pubitemid 47537095)
17. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Crohn's & Colitis Foundation of America, Bousvaros, A, Antonioli, DA, Colletti, RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007; 44: 653-674.
18. Akobeng AK., Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007; 96: 644-647. (Pubitemid 46653167)
19. Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol. 2004; 138: 491-498. (Pubitemid 39573630)
20. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005; 54: 479-487. (Pubitemid 40395499)
21. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology. 1999; 116: 557-565. (Pubitemid 29106763)
22. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003; 19: 849-861. (Pubitemid 37542305)